SOUTH SAN FRANCISCO, Calif., Dec. 08, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical
company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced
that Tassos Gianakakos, chief executive officer, will present at the BMO Capital Markets Prescription for Success Healthcare
Conference on Wednesday, December 14, at 9:20 AM Eastern Time, in New York.
In addition, Mr. Gianakakos will participate in a panel discussion, “New Generation of Orphan Companies,” with other
biopharmaceutical CEOs, at 9:40 AM Eastern Time.
To access the live webcast of MyoKardia’s presentation, please visit the “Events & Presentations” page within the Investors &
Media section of the MyoKardia website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia
website for 30 days following the conference.
About MyoKardia
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and
commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the
treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical
defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic
programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM,
and dilated cardiomyopathy, or DCM. MyoKardia’s most advanced product candidate, MYK-461, is an orally-administered small molecule
designed to reduce excessive cardiac muscle contractility leading to HCM and has been evaluated in three Phase 1 clinical trials.
MyoKardia is now studying MYK-461 in the Phase 2 PIONEER-HCM trial in symptomatic, obstructive HCM (oHCM), a subset of HCM. In
April 2016, the U.S. Food and Drug Administration (FDA) granted MYK-461 Orphan Drug Designation for the treatment of symptomatic
oHCM. MYK-491, the second clinical candidate generated by MyoKardia’s product engine, is designed to increase the overall force of
the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia intends to initiate a Phase 1 study of
MYK-491 in healthy volunteers in the first half of 2017. A cornerstone of the MyoKardia platform is the Sarcomeric Human
Cardiomyopathy Registry, or SHaRe, a multi-center, international repository of clinical and laboratory data on individuals and
families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia believes that SHaRe, currently consisting of
data from approximately 10,000 individuals, is the world’s largest registry of patients with heritable cardiomyopathies.
MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.
For more information, please visit www.myokardia.com.
Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200 beth@sternir.com Media Contact: Steven Cooper Edelman 415-486-3264 steven.cooper@edelman.com
